Mustang Bio Announces Safety And Efficacy Data From Complete Waldenstrom Macroglobulinemia Cohort Of Phase 1/2 Clinical Trial Of MB-106; Overall Response Rate Of 90% In Cohort With Durable Responses Observed, Says One Patient Remains In Complete Remission At 31 Months
Portfolio Pulse from Benzinga Newsdesk
Mustang Bio has announced promising safety and efficacy data from its Phase 1/2 clinical trial of MB-106 for Waldenstrom Macroglobulinemia. The trial showed a 90% overall response rate with durable responses, including one patient in complete remission for 31 months.
June 17, 2024 | 12:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mustang Bio's Phase 1/2 trial of MB-106 for Waldenstrom Macroglobulinemia shows a 90% overall response rate and durable responses, including one patient in complete remission for 31 months.
The high overall response rate and durable responses, including a long-term complete remission, are positive indicators for the efficacy of MB-106. This could lead to increased investor confidence and a potential rise in Mustang Bio's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100